It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Basal-like breast cancer (BLBC) is an aggressive subtype with a strong tendency to metastasize. Due to the lack of effective chemotherapy, BLBC has a poor prognosis compared with luminal subtype breast cancer. MicroRNA-221 and -222 (miR-221/222) are overexpressed in BLBC and associate with metastasis as well as poor prognosis; however, the mechanisms by which miR-221/222 function as oncomiRs remain unknown. Here, we report that miR-221/222 expression is inversely correlated with Notch3 expression in breast cancer cell lines. Notch3 is known to be overexpressed in luminal breast cancer cells and inhibits epithelial to mesenchymal transition (EMT). We demonstrate that miR-221/222 target Notch3 by binding to its 3′ untranslated region and suppressing protein translation. Ectopic expression of miR-221/222 significantly promotes EMT, whereas overexpression of Notch3 intracellular domain attenuates the oncogenic function of miR-221/222, suggesting that miR-221/222 exerts its oncogenic role by negatively regulating Notch3. Taken together, our results elucidated that miR-221/222 promote EMT via targeting Notch3 in breast cancer cell lines suggesting that miR-221/222 can serve as a potential therapeutic target in BLBC.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The Breast Center, Cancer Hospital of Shantou University Medical College, Shantou, China; ChangJiang Scholar’s Laboratory, Shantou University Medical College, Shantou, China; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
2 ChangJiang Scholar’s Laboratory, Shantou University Medical College, Shantou, China; Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Shantou University Medical College (SUMC), Shantou, China
3 The Breast Center, Cancer Hospital of Shantou University Medical College, Shantou, China; ChangJiang Scholar’s Laboratory, Shantou University Medical College, Shantou, China
4 ChangJiang Scholar’s Laboratory, Shantou University Medical College, Shantou, China
5 ChangJiang Scholar’s Laboratory, Shantou University Medical College, Shantou, China; Department of Pathology, The Cancer Hospital of Shantou University Medical College (SUMC), Shantou, China
6 Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
7 The Breast Center, Cancer Hospital of Shantou University Medical College, Shantou, China; ChangJiang Scholar’s Laboratory, Shantou University Medical College, Shantou, China; Xiang’an Hospital of Xiamen University, Xiamen, China